Skip to content

Posts tagged ‘ASCO Conference Coverage’

What’s hot at ASCO 2012?

May 15th, 2012

Daedalus

ASCO 2012 Meeting Chicago 225x300 Whats hot at ASCO 2012?The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) takes place in Chicago in just over two weeks time from June 1 – 5.  The ASCO abstracts will be publicly available tomorrow (May 16) at 6pm EDT.

We’re looking forward to being at ASCO, and picking up the latest data for new products and evaluating the impact this may have on our understanding of key pathways and drug development targets.

If you want to know what Sally Church, PhD predicts will be highlights of the ASCO 2012 meeting (in the absence of any abstract information) then watch her informative video and check out her ASCO preview post on Pharma Strategy Blog.

If you plan to be at ASCO 2012 and would like to meet up and discuss our capabilities, please contact us.

ASCO 2011 Annual Meeting Conference Coverage

June 3rd, 2011

Daedalus

Sally Church on Pharma Strategy Blog is aggregating the tweets from the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.  Twitter hashtag #ASCO11.

If you are unable to attend, you can follow what’s happening on Pharma Strategy Blog.

ASCO 2011 Video Preview Sally Church Pharma Strategy Blog 300x167 ASCO 2011 Annual Meeting Conference CoverageIn Sally’s video preview of ASCO 2011, she talks about ovarian cancer, metastatic melanoma and soft tissue sarcoma.  The video is well worth watching. We especially like the 20 second animated intro sequence!  Sally will be writing from ASCO on Pharma Strategy Blog and on twitter as @MaverickNY.

Pieter Droppert has also published an ASCO preview on Biotech Strategy Blog focused on prostate cancer. He is excited about data that will be presented on the use of circulating tumor cells (CTC) as a biomarker.  Pieter will be tweeting from ASCO as @3NT.

If you are attending ASCO we look forward to meeting you at what is set to be an exciting conference, otherwise do follow the action on Pharma Strategy Blog.

How resistance occurs to BRAF inhibitors such as PLX 4032 (vemurafenib)

May 13th, 2011

Daedalus

Icarus Consultants’ oncology expert, Sally Church has written extensively about BRAF inhibitors, and why melanoma patients develop resistance to PLX4032.

In a post on Pharma Strategy Blog, Sally reviews further research on mechanisms of resistance to BRAF inhibitors such as PLX 4032 (vemurafenib). Published in OncoTarget (an open access cancer journal), the article describes ERK dependent and ERK independent methods by which resistance occurs.

Sally notes that “as our knowledge of the science of metastatic melanoma improves, so do our opportunities for therapeutic intervention and improvement in outcomes.

Metastatic melanoma is expected to be a hot topic at the forthcoming annual meeting of the American Society of Clinical Oncology (ASCO) that Icarus Consultants will be attending.

You can read more on Pharma Strategy Blog.